Literature DB >> 3009009

Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors.

Y Pommier, D Kerrigan, R E Schwartz, J A Swack, A McCurdy.   

Abstract

Most DNA intercalators and epipodophyllotoxins inhibit mammalian topoisomerase II by trapping the enzyme within DNA cleavage complexes that can be detected in cells as protein-associated DNA strand breaks. We have characterized previously a line of Chinese hamster cells (DC3F/9-OHE cells) the resistance of which to the cytotoxic effect of intercalators and etoposide is associated with a reduced formation of protein-associated DNA strand breaks. In the present study, topoisomerases of these cells were compared to those of the parental sensitive cells (DC3F). NaCl extracts (0.35 M) of isolated DC3F/9-OHE nuclei did not form 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced DNA-protein linking, whereas DC3F nuclear extracts did. In addition, DC3F/9-OHE nuclear extract had an unusually high level of DNA linking activity in the absence of 4'-(9-acridinylamino)methanesulfon-m-anisidide. Topoisomerases II from DC3F/9-OHE and DC3F nuclei appeared similar qualitatively. DC3F/9-OHE nuclear extract had approximately twice less topoisomerase II molecules than did DC3F nuclear extract but similar topoisomerase II activity. Topoisomerase I activities appeared also similar in sensitive and resistant cells. However, part of DC3F/9-OHE topoisomerase I copurified with a DNA linking activity which was not present in DC3F nuclei. This unusual DNA linking activity was not sensitive to the stimulatory effect of 4'-(9-acridinylamino)methanesulfon-m-anisidide.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009009

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.

Authors:  Y Pommier; G Capranico; A Orr; K W Kohn
Journal:  Nucleic Acids Res       Date:  1991-11-11       Impact factor: 16.971

2.  Characterization of an etoposide-resistant human small-cell lung cancer cell line.

Authors:  K Minato; F Kanzawa; K Nishio; K Nakagawa; Y Fujiwara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 3.  Topoisomerases, new targets in cancer chemotherapy.

Authors:  J G Zijlstra; S de Jong; E G de Vries; N H Mulder
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

4.  In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.

Authors:  T Taki; T Ohnishi; N Arita; S Hiraga; T Hayakawa
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

Review 5.  DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.

Authors:  Y Pommier
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 6.  Drug resistance in brain tumors.

Authors:  L G Feun; N Savaraj; H J Landy
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Chromosome recombination and defective genome segregation induced in Chinese hamster cells by the topoisomerase II inhibitor VM-26.

Authors:  M Charron; R Hancock
Journal:  Chromosoma       Date:  1991-02       Impact factor: 4.316

8.  Potentiation of etoposide-induced cytotoxicity and DNA damage in CCRF-CEM cells by pretreatment with non-cytotoxic concentrations of arabinosyl cytosine.

Authors:  C M Chresta; R Hicks; J A Hartley; R L Souhami
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  "Atypical" multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3).

Authors:  G Cimoli; M Valenti; E Noviello; S Parodi; A Mazzoni; E Rovini; F De Sessa; P Russo
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

10.  Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer.

Authors:  G T Budd; R M Bukowski; A Lichtin; L Bauer; P Van Kirk; R Ganapathi
Journal:  Invest New Drugs       Date:  1993-02       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.